CRL
Charles River Laboratories International, Inc.
Set alert
- YTD
- +80.17%
- 1 year
- +100.66%
- Open
- 372.99
- Prev close
- 376.10
- Mkt cap
- 17.16B
- Vol
- 1.50M
- Avg vol
- 1.02M
- EPS
- -4.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 351.98
- High
- 374.40
- Forward P/E
- 28.20
- Beta
- 1.40
- Short ratio
- 2.77
- Inst. own
- 122.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 300.55
- 200-d avg
- 221.07
- 1y target
- 318.87
Key statistics
- Market cap
- 17.16B
- Enterprise value
- 20.85B
- Trailing P/E
- 0.00
- Forward P/E
- 28.20
- PEG ratio
- 0.12
- Price / sales
- 4.29
- Price / book
- 6.04
- EPS (TTM)
- -4.80
- Beta
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.96%
- Revenue (TTM)
- 4.00B
- Revenue growth
- -2.70%
- Free cash flow
- 468.86M
- Total cash
- 192.02M
- Total debt
- 3.03B
- Return on equity
- -7.52%
- Shares outstanding
- 47.74M
- Short % of float
- 6.86%
- 50-day average
- 300.55
- 200-day average
- 221.07
Analyst view
Consensus: buy
- Target (low)
- 145.00
- Target (mean)
- 318.87
- Target (high)
- 390.00
- Strong buy3
- Buy11
- Hold2
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 2.97.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 27, 2026 | 2.97 | — | — | — |
| Aug 5, 2026 | Jun 27, 2026 | 2.74 | 3.02 | +0.28 | +10.22% |
| May 7, 2026 | Mar 28, 2026 | 1.96 | 2.06 | +0.10 | +5.10% |
| Feb 18, 2026 | Dec 27, 2025 | 2.33 | 2.39 | +0.06 | +2.58% |
| Nov 5, 2025 | Sep 27, 2025 | 2.32 | 2.43 | +0.11 | +4.74% |
| Aug 6, 2025 | Jun 28, 2025 | 2.50 | 3.12 | +0.62 | +24.80% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 28, 2026 | Jefferies | main | Buy | Buy |
| Sep 25, 2026 | Deutsche Bank | main | Buy | Buy |
| Sep 25, 2026 | TD Cowen | main | Buy | Buy |
| Sep 25, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Sep 25, 2026 | RBC Capital | main | Outperform | Outperform |
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- criver.com
News
- Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
- Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
- Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen
- Charles River Leverages Virtual Control Groups in GLP Studies
- Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock
- 8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC
- Ariel Fund Q3 2026 Leaders And Laggards
- Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs
- $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today
- SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
Your note
Sign in to keep a note on CRL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBO WILLIAM D | Officer | Stock Gift | Nov 6, 2024 | 0 |
| COLEMAN GLENN G | Chief Financial Officer | Stock Award(Grant) | May 28, 2026 | 27,752 |
| CREAMER VICTORIA L | Officer | Sale | Aug 5, 2026 | 30,051 |
| FOSTER JAMES C | Director | Sale | Oct 21, 2026 | 233,410 |
| GIRSHICK BIRGIT | Chief Executive Officer | Stock Gift | Aug 18, 2026 | 79,288 |
| LAPLUME JOSEPH W | Officer | Stock Gift | Aug 9, 2026 | 31,041 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.88% | 4,239,752 | 1.52B | Jun 29, 2026 |
| Blackrock Inc. | 7.96% | 3,798,560 | 1.37B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.60% | 3,149,288 | 1.13B | Jun 29, 2026 |
| Invesco Ltd. | 6.25% | 2,984,785 | 1.07B | Jun 29, 2026 |
| Harris Associates L.P. | 4.69% | 2,241,144 | 805.58M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.63% | 2,210,979 | 794.74M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Contrafund | 3.82% | 1,825,159 | 656.05M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.21% | 1,530,171 | 550.02M | Jun 29, 2026 |
| HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund | 3.14% | 1,498,000 | 538.46M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 1,247,732 | 448.50M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.31% | 1,104,850 | 397.14M | Jun 29, 2026 |
| ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund | 1.64% | 784,906 | 282.13M | Aug 30, 2026 |